Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland

Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland

Show other versions (1)

In May 2020, larotrectinib (Vitrakvi®) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. While in certain types of tumors an NTRK gene fusion is often...

Full description

Bibliographic Details
Main Authors: Holger Moch, Gieri Cathomas, Milo Frattini, Wolfram Jochum, Erik Vassella, Laurence de Leval, Joachim Diebold, Christian Britschgi, Thomas McKee, Lukas Bubendorf
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2021-03-01
Series:healthbook TIMES. Oncology Hematology
Subjects:
tumor-agnostic agent
trk inhibitor
ntrk gene fusion
next generation sequencing (ngs)
immunohistochemistry (ihc)
fluorescence in situ hybridization (fish)
Online Access:https://onco-hema.healthbooktimes.org/article/25715-use-of-diagnostic-algorithms-for-ntrk-fusion-positive-tumors-in-pathology-institutes-in-switzerland

Internet

https://onco-hema.healthbooktimes.org/article/25715-use-of-diagnostic-algorithms-for-ntrk-fusion-positive-tumors-in-pathology-institutes-in-switzerland

Similar Items